RxDoctor Payments Data

Garrett Whittaker

Family · Torrington, CTNPI 1174149462

Payments from drug & device makers

$3,281in general payments, 2019–2025

Across 120 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$402
  • Sumitomo Pharma America, Inc.$382
  • AstraZeneca$267
  • Bayer$245
  • Exact Sciences$175
  • Pfizer$163
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,281 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$33,486
Medicare patients
197
Services billed
2,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron19$18,447
MyrbetriqMirabegron13$12,192
Methenamine Hippurate55$6,205
Tamsulosin Hcl160$2,685
Dutasteride16$452
Finasteride29$383
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip24$310
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$203
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$170
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$145
Ibuprofen14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$382$18,44719 claims
Astellas Pharma US IncMyrbetriq$45$12,19213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →